Different types of COVID-19 vaccines which are scientifically proven to be effective and safe are introduced through the National Immunization Programme to get the maximum effect of preventing the COVID-19 transmission, severe morbidity and mortality in the country.

The Sinopharm, SARS-CoV-2 Vaccine (Vero Cell), BBIBP-CorV -COVID-19 vaccine is an inactivated vaccine made of virus particles grown in a culture and doesn’t have disease-producing capability.

- This SARS-CoV (Vero Cell), Inactivated vaccine is formulated with SARS-CoV-2 strain which is inoculated on the Vero cells for culturing. The virus is inactivated with β-proplotactone, concentration and purification were done and adsorbed with aluminium adjuvant to form the liquid vaccine.
- It is expected to develop antibodies against the SARS-CoV-2 after vaccination, to prevent the COVID-19 disease.
- The vaccine product is a semi-transparent turbid suspension with slight white colour. It can be layered due to precipitation, and the precipitation can be easily dispersed by shaking.
- The vaccine is stable in storage at 2°-8°C.

**Target group:**
Target groups to be vaccinated will be informed by the Ministry of Health as with the vaccine supply and considering the epidemiological assessment for the best impact for prevention of transmission, morbidity and mortality.

This product can be used for people aged 18 years old and above, but the vaccination category and the age will be informed by the Epidemiology Unit, Ministry of Health considering the best impact of prevention of transmission, prevention of morbidity and mortality.

**Vaccine stock requirement:**
Number of vaccine doses and number vaccinated will be the same as the vaccine product available at present is the single dose vial presentation.

**Method or Administration:** The recommended administration is through intramuscular route (IM), preferably to the upper part of the left arm.

**Active composition:** vial contains 0.5mL of product for each administration by intramuscular Injection, in which each dose contains 6.5U of inactivated SARS-CoV-2 antigen.

**Other excipients** of the vaccine include, Disodium hydrogen phosphate, Sodium chloride, Sodium dihydrogen phosphate, Aluminium hydroxide.
**Dosage schedule:** recommend to vaccinate with 2 doses (each of 0.5 ml) into the deltoid muscle (left side), at 4 weeks interval with each dose of 0.5ml, intramuscular (consistent of 6.5U of inactivated SARS-CoV-2 antigen per dose).

If the administration of the second dose is delayed beyond the duration of 4 weeks, it should be administered at the earliest possible opportunity. (Requirement of any additional booster doses will be informed after the global recommendations with further evidence).

**Storage**

- SARS-CoV-2 Vaccine (Vero Cell), Inactivated (BBIBP-CorV) vaccine should be stored at \(+2^0\) C to \(+8^0\) C temperature at all levels at all the time.
- The vaccine is freeze sensitive and should not expose to freezing temperature at any time.
- The vaccine is heat sensitive and should protect from direct sunlight.
- During the clinic session, vaccine vials should be kept in the vaccine carrier until taking a vial out for the vaccination.

**Adverse events that have been reported with the SARS-CoV-2 Vaccine (Vero Cell).**

**Inactivated include:** [Very common (≥10%), common (1-10%), occasional (0.1-1%), rare (0.01-0.1%), very rare (<0.01%)]

1. **Local reactions: at the injection site**
   - **Very common:** Pain;
   - **Occasional:** Redness, swelling, induration, pruritus;
   - **Rare:** Erythema

2. **Systemic reactions**
   - **Very common:** Headache
   - **Common:** Fever, fatigue, myalgia, arthralgia, cough, dyspnea, nausea, diarrhea, pruritus;
   - **Occasional:** Dizziness, anorexia, vomiting, oropharyngeal pain, dysphagia, running nose, constipation, hypersensitivity;
   - **Rare:** acute allergic reaction, lethargy, drowsiness, difficulty falling asleep, sneezing, nasopharyngitis, nasal congestion, dry throat, influenza, hypoesthesia, limb pain, palpitations, abdominal pain, rash, abnormal skin mucosa, acne, ophthalmodynia, ear discomfort, lumphadenopathy;
   - **Very rare:** Chills, taste dysfunction, loss of taste, paresthesia, tremor, attention disorder, epistaxis, asthma, throat irritation, tonsillitis, physical discomfort, neck pain, jaw pain, neck lump, mouth ulcers, toothache, esophagus disorders, gastritis, fecal discoloration, ophthalmodynia, blurred vision, eye irritation, earache, tension, hypertension, hypotension, urinary incontinence, delayed menstruation.
**Contraindications:**

1. Individuals who are allergic to any component of this product (including excipients—Disodium hydrogen phosphate, Sodium chloride, Sodium dihydrogen phosphate, Aluminium hydroxide).
2. Immediate or delayed onset allergic /anaphylactic reactions after a previous dose of the SARS-CoV-2 (Vero Cell), Inactivated Vaccine.
3. Patients with uncontrolled epilepsy or other progressive nervous system diseases, with a history of Guillain-Barre syndrome and any adverse nervous system reaction occurred after a previous dose of the same vaccine product.
4. Pregnant and lactating women lactation (lactation is considered only for the initial 6 months after delivery) [not done clinical trials so far for adequate evidence).
5. <18 years (not done clinical trials so far)

**Special Warnings and Precautions for Use**

1. Intravascular injection is strictly prohibited. There is no safety and efficacy data of the vaccine after subcutaneous and intradermal injection.
2. Use with caution in patients with acute diseases, acute onset of chronic diseases, severe chronic diseases, allergies and fever - advised to get clinician advise if necessary.
3. Use with caution in patients who have diabetes and those with a history or family history of convulsions, epilepsy, encephalopathy or mental illness.
4. Use with caution in patients who have decrease in platelets or clotting disorders (e.g. clotting factor deficiency, coagulopathy, platelet disorders) because of the risk of bleeding which may occur during intramuscular administration of the vaccine. Need to get specialized opinion if need of the disease condition.
5. Use with caution in patients with impaired immune function (such as malignant tumor, nephrotic syndrome, AIDS patients, etc.) because the safety and efficacy data are not available, and such population should be vaccinated on an individual basis.
6. People injected with immunoglobulin should be vaccinated with this product at least 1 month apart, so as not to affect the immune efficacy.
7. The concomitant clinical trials on this vaccine in combination with other vaccines have not yet been conducted. Consult a physician for advice if other vaccines have to be immunized at the same time.

**Temporary postponement of vaccination:** following conditions are required temporary postponement of the vaccination (vaccination should be postponed for 4-8 weeks)

- Any signs and symptoms suggestive of acute SARS-CoV 2 infection or suffering from any other acute illness who are not fit for the vaccination.
- Already diagnosed SARS-CoV 2 patient who have received anti-CoV 2 monoclonal antibodies or convalescent plasma as a treatment option (at least 1 month).
Following conditions are not contraindications for the vaccination:

- Persons with a past history of SARS-CoV 2 infection (by patient history, RT PCR positive report or sero positivity): vaccination should be done irrespective of the previous COVID-19 disease conditions (COVID-19 confirmed cases can be vaccinated 2 weeks after the recovery)

Other logistic requirements

- 0.5ml AD syringes (number equal to number of doses estimated)
- Adequate cotton swabs
- Sharp disposal safety boxes (1 standard box = 10 L, can hold 100 syringes with needles)
  - Estimated number of AD syringes /100 = required number of safety boxes
- Assess the adequacy of vaccine carriers to distribute vaccines to all hospital clinics and MOH central clinics.
- Assess the adequacy of ice packs for vaccine transport to all clinics (if inadequate need to re-distribute). Make sure adequate ice packs are in freeze and stored.
- Vaccines should store in RMSD-cold rooms and preferably in vaccine storing ILR, (Net capacity 200 L with standard capacity 90L) at hospitals and MOH settings adhering to National immunization vaccine storage guidelines. It is strongly advised not to store vaccines with other pharmaceutical items other than with EPI vaccines.
- Emergency tray with essential items to attend immediate Adverse Events Following Immunization (AEFI) as with National guidelines should be available in all immunization clinic centres.

Implementation of the vaccination

- The campaign mode vaccination for 1st round and 2nd round of vaccination needs to be conducted as with the identified categories and dates agreed with the Epidemiology Unit, Ministry of Health as with the evolving requirement of the country for the best impact.
- The vaccination data should be updated on the same day to the National Immunization Programme, Epidemiology Unit, Ministry of Health.
- Vaccine stock request from the RMSD needs to be done by using the Monthly Stock Return of Vaccine and Injection Safety Devices (Annexure 1)
- Vaccine stocks received to the institution are required to be entered into the existing Vaccine/drugs stock ledger in the institution and into the existing MOH office-Vaccine Movement Register (Blue colour book) (format: Annexure 2)
- Vaccine stock request to the clinic, should be based on the existing Clinic-Vaccine Movement Register (Yellow colour book) (format: Annexure 3)
- At the end of the clinic session, if any remaining vials returned from the clinic, needs to be stored separately (in returned unopened vial box) in the Ice Lined Refrigerator (ILR) and should be used as the priority in the next clinic session.
- At the end of the clinic session, Vaccine Movement Registers need to be balanced, and Immunization Clinic Returns need to be completed and sent to the Regional Epidemiologist (Annexure 8)
Remaining vaccine stocks at the end of the initial round of the campaign should store securely at 2º-8ºC until the 2nd round of the campaign.

These remaining vaccine stocks should mention in the monthly stock return to RMSD with a copy to the Regional Epidemiologist.

After the 2nd dose of the campaign all remaining vaccine vials should return to RMSD by duly completing the Monthly Stock Return of Vaccine and Injection Safety Devices Vaccine Stock Return (Annexure 1)

Vaccine stocks should not be kept in any of the institutional refrigerators after the 2nd dose of the campaign.

Only selected institutions will allow to keep limited amount of vaccine stocks for the use of vaccination-postponed individuals.

**Immunization clinic functioning**

- Immunization clinic centres should be established in hospitals, MOH offices and in field. Immunization clinic centres to vaccinate relevant selected target groups as instructed by the Ministry of Health.
  - Other field level vaccination centres can be organized by assessing the resources, availability of health care staff, other support staff and facilities to conduct the clinic and attending emergency situations.
    - All clinic field level centres vaccinating is advised to communicate with areas MOH/ Regional Epidemiologist/District and Provincial Consultant Community Physicians, for the “emergency tray” preparation and arrangements to attend any AEFI emergencies.
- Implementation of the immunization clinics can be done adhering to National guidelines of vaccination under the guidance and supervision by the immunization supervisory health teams from the RDHS/PDHS/ Epidemiology Unit / teams from the Ministry of Health.
- Vaccination clinics should function with adequate human resource to ensure smooth functioning of the clinic.
- Volunteer support can be obtained for services outside the clinic for crowd control, guiding for information and targeted advices for the vaccination in improving the campaign efficiency.
- Take measures to prevent unnecessary gatherings of the crowd in and around the vaccination clinic.
- All precautionary measures need to be taken by the vaccination teams and supporting individuals to the clinic during the clinic sessions in prevention of possible COVID-19 transmission.
- Clinic setting should arrange as 1) waiting area 2) eligibility screening with consent to vaccinate 3) registration and issuing the vaccination card 4) marking of a tally sheet, vaccination and next appointment date 5) AEFI observation area
- Clinic station arrangement should be organizing in a way that minimum time wasting at different stations to get the maximum efficiency in the clinic.
• Immunization Clinic registration format (Annexure 4) is provided and photocopied sheets of the format can be used for the registration or the printed register provided to identify eligible population can be used for the registration of the vaccination during the session.
• In addition to this, ensure proper registration data is entered into the Electronic web based person information registration system (tracker) developed by the Ministry of Health.
• All registration formats / Vaccination Registers should be duly filed in the institution for future review requirements, next dose reminders and if any other official requirements.
• The same Register / Register format used can be utilized for the 2nd dose vaccination or a fresh Register format can be used for the 2nd dose for the convenience. But, ask about the initial dose (1st dose) from the history (H) or check from the “Vaccination card” (C) to ensure completeness of the vaccination.
  ▪ Mark a tick at the appropriate column for the 1st dose, if information is gathered from the Immunization card as “✓ / C” or if information is gathered from the history as “✓ / H”.
• It is not advisable to interchange vaccination with different COVID-19 vaccine types (as with evidence so far).
• Take measures to follow up the 2nd dose of the vaccination using the same vaccine product.
• All persons coming for the vaccination should screen adequately for the eligibility, contra-indications and high risk conditions should be asked before vaccination.
• Consent form given in 3 languages should be signed at the most comfortable language for the consent to vaccination (Annexure 5)
• Previous COVID-19 positive and recovered patients should be vaccinated irrespective of the previous COVID-19 disease condition and can vaccinate 2 weeks after the recovery.
• In any doubtful cases for the eligibility, should contact a Consultant/Medical Officer in the hospital/ MOH in the area/ Regional Epidemiologist/Medical Officers-MCH/Provincial or District CCP/ Epidemiology Unit for an advice.
• Tally sheet developed for age group (Annexure 6), sex and health status should be properly completed and provided to the Regional Epidemiologist/Epidemiology Unit at the end of the day with the clinic return.
• Register the person (electronic web based (tracker) and paper based - Annexure 4) and issue “COVID-19 vaccination card” – Annexure 7 (important to mention the name of the vaccine)
• Advice to write the vaccination card in English language in case if required for international use.
• Shake the vaccine vial gently to mix the solution uniformly before withdraw the SARS-CoV-2 (Vero Cell), Inactivated Vaccine dose from the vial.
Advise to use 0.5ml AD syringes at all possible instances and carefully withdraw the correct dose (0.5ml) by keeping the upper edge of the plunger at the 0.5ml mark in the syringe without any air bubbles.

Vaccination should be given as IM injection (advise to withdraw and vaccinate by the same person adhering to minimum handling, in order to minimize the possible contamination).

SARS-CoV-2 Vaccine (Vero Cell), Inactivated (BBIBP-CorV) vaccine 0.5 ml IM to be given to upper arm preferably on left side.

After vaccination, they should be observed for a minimum of 20 minutes in the clinic for AEFI.

All vaccination procedure and vaccine management in general should be in accordance with the National guidelines given in the Immunization Handbook (3rd Edition), Epidemiology Unit, Ministry of Health.

Vaccine safety in Immunization clinics should be maintained and managed according to the circular “Initial Management of Anaphylaxis at Field level” (circular number 01-20/2001, dated 23/08/2011) and National guidelines given in the Immunization Handbook (3rd Edition), Epidemiology Unit, Ministry of Health.

Any reported AEFI identified at the clinic needs to be entered in the Clinic / Hospital AEFI Register and inform to the Epidemiology Unit, Regional Epidemiologist and MOH in the area using AEFI form I (available as carbonated 3 copies in a book : format - Annexure 9)

At the end of the clinic compile all the data and
  o complete the Immunization clinic return (Annexure 8) in two copies and send one copy to the Regional Epidemiologist and keep one copy at the institution.
  o Tally sheet summary should enter into the “eNIP” web based electronic National Immunization Programme database, together with the target number expected to be vaccinated.

Disposal of sharps in safety boxes and waste bins should be done preferably as incineration and according to the standard accepted practices applied in the routine Immunization clinics.

All used vaccine vials should be incinerated.

All vaccine stocks related data, if any vaccine wastage information and vaccination related data should submit to the Regional Epidemiologist in the provided Immunization clinic return (Annexure 8).

Epidemiology unit, Ministry of Health, 08/05/2021
<table>
<thead>
<tr>
<th>Institution</th>
<th>Month</th>
<th>1. Stock at the beginning of the month</th>
<th>2. Stocks received during the month</th>
<th>3. Stocks distributed at end of the month</th>
<th>4. Balance stocks in hand now</th>
<th>5. Stocks requested</th>
</tr>
</thead>
<tbody>
<tr>
<td>Others</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety boxes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Syringes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 ml disposable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Syringes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.5 ml AD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Syringes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 ml disposable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AD syringes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.05 ml BCG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fe doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AIT doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rubella doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DT doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MR doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TT doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles Doses</td>
<td></td>
<td>10 Dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5 Dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBV Doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10 Dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 Dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPV doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DPT doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BCG doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Name of the item - .............................................

<table>
<thead>
<tr>
<th>Date DD/MM/YYYY</th>
<th>No. of doses / items in hand (B)</th>
<th>Place of distribution (Clinic/ School) (C)</th>
<th>No. of doses / items issued (D)</th>
<th>Batch No. (E)</th>
<th>No. of vaccinations performed (F)</th>
<th>No. of doses / items used (G)</th>
<th>No. of doses / items Returned (H)</th>
<th>Balance in hand (I)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Clinic Vaccine Movement Register Format

<table>
<thead>
<tr>
<th>Date: .........................</th>
<th>Type of vaccine/item</th>
<th>No. of doses /items issued to the clinic</th>
<th>Batch number</th>
<th>No. of vaccinations performed</th>
<th>No. of doses /items used</th>
<th>No. of doses /items returned</th>
<th>No. of doses /items required for the next clinic</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>BCG</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>PVV</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>OPV</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>LJEV</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>MMR</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>DPT</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>DT</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>TT</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>aTd</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>BCG diluents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>LJEV diluents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>MMR diluents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>0.05 ml syringes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>0.5 ml syringes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>2ml syringes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>5 ml syringes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Safety boxes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Signature of assigned person at MOH office ................................ Signature of assigned PHM at clinic .................................................
<table>
<thead>
<tr>
<th>Reg. Number</th>
<th>Name &amp; NIC Number</th>
<th>Age</th>
<th>Sex</th>
<th>Address</th>
<th>Contact number</th>
<th>Date of Covid 19 Vaccination</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1st Dose 2nd Dose 3rd Dose 4th Dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
COVID-19 vaccination

I have received the opportunity to ask questions, receive relevant information and clarify my doubts on COVID-19 vaccines and vaccination, given from the vaccination centre today from the health staff in the centre.

After I understand the benefits and possible rare adverse events of the COVID-19 vaccine, I have decided and consented to get the vaccination.

Signature: ......................................................... Date: .............................................
### MINISTRY OF HEALTH

**COVID-19 vaccination : Immunization Clinic Tally Sheet - Different age groups**

<table>
<thead>
<tr>
<th>Date</th>
<th>Institution name</th>
<th>District</th>
<th>MOH area</th>
<th>Clinic centre name</th>
<th>Vaccine Name</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Age groups

- **60 years and above**
  - **Male known healthy**: 1 2 3 4 5
  - **Male known comorbid conditions**: 6 7 8 9 10
  - **Female known healthy**: 1 2 3 4 5
  - **Female known comorbid conditions**: 6 7 8 9 10

- **50 – 59 years**
  - **Male known healthy**: 1 2 3 4 5
  - **Male known comorbid conditions**: 6 7 8 9 10
  - **Female known healthy**: 1 2 3 4 5
  - **Female known comorbid conditions**: 6 7 8 9 10

- **40 – 49 years**
  - **Male known healthy**: 1 2 3 4 5
  - **Male known comorbid conditions**: 6 7 8 9 10
  - **Female known healthy**: 1 2 3 4 5
  - **Female known comorbid conditions**: 6 7 8 9 10

- **30 – 39 years**
  - **Male known healthy**: 1 2 3 4 5
  - **Male known comorbid conditions**: 6 7 8 9 10
  - **Female known healthy**: 1 2 3 4 5
  - **Female known comorbid conditions**: 6 7 8 9 10

- **20 – 29 years**
  - **Male known healthy**: 1 2 3 4 5
  - **Male known comorbid conditions**: 6 7 8 9 10
  - **Female known healthy**: 1 2 3 4 5
  - **Female known comorbid conditions**: 6 7 8 9 10

- **Less than 20 years**
  - **Male known healthy**: 1 2 3 4 5
  - **Male known comorbid conditions**: 6 7 8 9 10
  - **Female known healthy**: 1 2 3 4 5
  - **Female known comorbid conditions**: 6 7 8 9 10

*Diabetes mellitus, Hypertension, Cardio vascular diseases, Cerebro-vascular diseases, Kidney diseases, Liver diseases, Chronic lungs diseases, Malignancies, History of transplant, Immune compromised patients and any other chronic medical conditions.*
COVID-19 Vaccination card

**Instructions**

Make sure you protect this COVID-19 vaccination card.

Remember to get the next dose of the COVID-19 vaccine on due date and time as instructed by the Health staff.

**COVID-19 vaccination details**

<table>
<thead>
<tr>
<th>COVID-19 vaccine</th>
<th>Name of the Vaccine</th>
<th>Place of vaccination</th>
<th>Date of Vaccination</th>
<th>Batch number</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose</td>
<td></td>
<td></td>
<td>DD/MM/YYYY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2&lt;sup&gt;nd&lt;/sup&gt; dose</td>
<td></td>
<td></td>
<td>DD/MM/YYYY</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For further information contact: Medical Officer of Health in your area or Epidemiology Unit, Ministry of Health.

**Details**

- **Name:**
- **NIC number/Passport number:**
- **Age:**
- **Sex:**
- **Address:**
- **Contact number:**
- **District:**
- **MOH area:**
- **Grama Niladari area:**
- **Serial Number in the register:**

**COVID-19 vaccination details**

<table>
<thead>
<tr>
<th>COVID-19 vaccine</th>
<th>Name of the Vaccine</th>
<th>Place of vaccination</th>
<th>Date of Vaccination</th>
<th>Batch number</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose</td>
<td></td>
<td></td>
<td>DD/MM/YYYY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2&lt;sup&gt;nd&lt;/sup&gt; dose</td>
<td></td>
<td></td>
<td>DD/MM/YYYY</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Details**

- **Number:**
- **Date:**
- **Remarks:**

**Annexure 7**
COVID-19 vaccination campaign: Immunization Clinic Return

Vaccine name: ……………………………………………………………………………

(to be completed in 2 copies by the responsible officer in the hospital /MOH office/ field clinic /other institutional clinic and return one copy to Regional Epidemiologist at the end of the clinic session and keep one as a clinic copy)

District: ………………………………… Institution name: ……………………… MOH area: ………………………………………

Clinic name: ………………………………… Date: ……………………………

<table>
<thead>
<tr>
<th>Date</th>
<th>Total estimated/actual number to be vaccinated (Target)</th>
<th>Number of vaccine doses received</th>
<th>Total number vaccinated (per day)</th>
<th>Number of vaccine doses returned</th>
<th>Number of doses discarded</th>
<th>Coverage %</th>
<th>Wastage %</th>
<th>Number of AEFI reported</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A</td>
<td>B</td>
<td>C</td>
<td>D</td>
<td>F = B - (C + D)</td>
<td>C / A X 100 %</td>
<td>F / (B – D) X 100 %</td>
<td>G</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Name: ……………………………………………….. Designation: ……………………………….. Signature: ………………………………..

Date: ………………………………………………. 
### Notification Form for Adverse Events Following Immunization (AEFI)

#### Patient Information

Name: MOH Division:

Age: ☐ months/years ☐ Sex: Male ☐ Female ☐ Telephone:

Name & address of the Parent/Guardian:

#### Information on the vaccine (primary suspected and other)

<table>
<thead>
<tr>
<th>Vaccine (Generic Name)</th>
<th>Vaccine (Trade name)*</th>
<th>Route</th>
<th>Dose (1st 2nd 3rd 4th)</th>
<th>Batch/Lot Number</th>
<th>Expiry date</th>
<th>VVM Status (I, II, III, IV)</th>
</tr>
</thead>
</table>

Diluent used: Yes ☐ No ☐ If "yes", Diluent batch/lot number: Expiry date of Diluent:

*Trade name is necessary only in private sector immunization*

Place vaccine administered: Date:

Person vaccine administered: Doctor ☐ PHNS/Nurse ☐ PHM ☐ PHI ☐ Time: am/pm

#### Adverse Events

<table>
<thead>
<tr>
<th>Local Adverse Events Requiring investigation</th>
<th>Injection site abscess ☐</th>
<th>BCG Lymphadenitis ☐</th>
<th>Severe local reaction ☐</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>CNS Adverse Events Requiring Investigation</th>
<th>Vaccine associated paralytic poliomyelitis ☐</th>
<th>GBS ☐</th>
<th>Encephalopathy ☐</th>
<th>Encephalitis ☐</th>
<th>Meningitis ☐</th>
<th>Seizures Febrie ☐</th>
<th>Seizures Afebrile ☐</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Other Adverse Events Requiring Investigation</th>
<th>Anaphylaxis ☐</th>
<th>Persistent screaming ☐</th>
<th>Osteitis / Osteomyelitis ☐</th>
<th>Hypotonic Hypeoresponsive Episode ☐</th>
<th>Toxic Shock Syndrome ☐</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Adverse Events Not Requiring Investigation</th>
<th>Allergic reaction ☐</th>
<th>Arthralgia ☐</th>
<th>High fever (&gt;39°C / 102°F) ☐</th>
<th>Nodule at the injection site ☐</th>
</tr>
</thead>
</table>

| Other Adverse Events b) | |
|------------------------| |

**Instruction:** Before reporting an AEFI, please refer to the definition for the relevant AEFI given in overleaf and make sure that reporting event agrees with the criteria stipulated in the definition.

Date & Time onset of adverse event:

Date & Time referring to medical care:

#### Medical History/Other

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Hospitalized: Yes ☐</th>
<th>No ☐</th>
<th>If &quot;Yes&quot;: Hospital: BHT: Still in the hospital ☐</th>
<th>Discharged ☐</th>
<th>Outcome: Recovered completely ☐</th>
<th>Partially recovered ☐</th>
<th>Death ☐</th>
</tr>
</thead>
</table>

#### Reporting source

Date of the notification: Institution & Designation: Telephone:

Name & Signature of the notifying officer/General Practitioner:

(Medical Officers who attend any patient suffering from Adverse Effects Following Immunization shall notify in this form to the Medical Officer of Health the area of the patients residence)
Definitions of Adverse Events Following Immunization

All of the following adverse events should be reported if temporally related to immunization. Unless otherwise specified this includes all such events occurring within four weeks of a vaccine administration.

1. Local Adverse Events

a. Injection – Site Abscesses
Occurrence of a fluctuant or draining fluid – filled lesion at the site of injection with or without fever.

Bacterial: Existence of purulence, inflammatory signs, fever, positive Gram stain, positive culture, or finding of neutrophils. Predominance of content will support a bacterial site abscess, but the absence of some of these signs will not rule it out.

Sterile: There is no evidence of bacterial infection following investigation.

b. Lymphadenitis (includes Suppurative Lymphadenitis)
Occurrence of either

At least one lymph node, 1.5 cm in size (one adult finger width) or larger or a draining sinus over a lymph node.

Almost exclusively caused by BCG and occurring within 2 to 6 months after receipt of BCG and on the same side as inoculation (mostly axillary).

c. Severe Local Reaction: Redness and/or swelling centered at the site of injection and one or more of the following:

1. Swelling beyond the nearest joint;
2. Pain, redness and swelling for more than 3 days duration; or
3. Requires hospitalization.

2. Central Nervous System Adverse Events

a. Vaccine Associated Paralytic Poliomyelitis
Acute onset of flaccid paralysis within 4-30 days of receipt of oral poliovirus vaccine (OPV), or within 4-75 days after contact with a vaccine recipient, with neurological deficits remaining 60 days after onset, or death.

b. Guillain-Barre Syndrome (GBS)
Acute onset of rapidly progressive, ascending, symmetrical flaccid paralysis, without fever at onset of paralysis and with sensory loss. Cases are diagnosed by cerebrospinal fluid (CSF) investigation showing dissociation between cellular count and protein content. GBS occurring with 30 days after immunization should be reported.

c. Encephalopathy:
Cases occurring within 72 hours after vaccination should be reported. Encephalopathy is an acute onset of major illness temporally linked with immunization and characterized by any two of the following three conditions: Seizures; Severe alteration in level of consciousness lasting for one day or more; and distinct change in behavior lasting one day or more.

d. Encephalitis:
(Any encephalitis occurring within 1 – 4 weeks following immunization should be reported). Encephalitis is characterized by the above mentioned symptoms and signs of cerebral inflammation and, in many cases, CSF pleocytosis and/or virus isolation.

e. Meningitis:
Acute onset of major illness with fever, neck stiffness/positive meningeal signs (Kernig, Brudzinski). Symptoms may be subtle or similar to those of encephalitis, CSF examination is the most important diagnostic measure: CSF pleocytosis and/or detection of microorganism (Gram stain or isolation).

f. Seizures:
Seizures lasting for several minutes to more than 15 minutes and not accompanied by focal neurological signs or symptoms. Seizures may be Febrile Seizures or Afebrile.

3. Other Adverse Events requiring investigation

a. Anaphylactic shock:
Circulatory failure (e.g. alteration of the level of consciousness, low arterial blood pressure, weakness or absence of peripheral pulses, cold extremities secondary to reduced peripheral circulation, flushed face and increased perspiration) with or without bronchosospasm and/or laryngospasm/laryngeal edema leading to respiratory distress occurring immediately after immunization.

b. Persistent Screaming:
Inconsolable continuous crying lasting at least 3 hours accompanied by high-pitched screaming

c. Hypotonic-Hypo responsive Episode (HHE) (shock collapse):
Sudden onset of pallor or cyanosis, decreased level or loss of responsiveness, decreased level of muscle tone (occurring within 48 hours of vaccination). The episode is transient and self limiting

d. Osteitis/Osteomyelitis:
Inflammation of the bone either due to BCG immunization (occurring within 6 to 16 months after immunization) or caused by other bacterial infection

e. Toxic-Shock Syndrome:
Abrupt onset of fever, vomiting and watery diarrhea within a few hours of immunization, often leading to death within 24-48 hours.

4. Other adverse events not requiring investigation

a. Allergic Reaction:
Characterized by one or more of the following:
1. Skin manifestations (e.g. hives, eczema);
2. Wheezing;
3. Facial or generalized oedema

b. Arthralgia:
Persistent joint pain lasting longer than 10 days. Transient: Joint pain lasting up to approximately 10 days.

c. High Fever:
The Endogenous elevation of at least one measured body temperature >39°C

d. Nodule at the injection site:
Presence of a discrete or well demarcated firm soft tissue mass or lump at the injection site that is sometimes referred to as a subcutaneous nodule, antigen cyst or granuloma, in the absence of abscess formation, erythema and warmth.

5. Other severe and unusual events occurring within 4 weeks after immunization and not covered under categories 1-4.

Any unexplained sudden death of a vaccine recipient temporarily linked (with 4 weeks) to immunization, where no other clear cause of death can be established, should be reported. In addition, any unusual events should be reported.